BC Extra | Jan 7, 2020
Company News

VectivBio reunites ex-Therachon management, VCs for short bowel program

Eight months after a venture syndicate gained an exit via the sale of dwarfism company Therachon to Pfizer, the same investors have reunited to supply a $35 million round for VectivBio, a new spinout created...
BC Extra | May 17, 2019
Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval  FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support,...
BC Extra | May 8, 2019
Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

Rather than file for an IPO as it had been planning to do, Therachon has elected to take a buyout offer from Pfizer, handing the pharma a clinical program to treat achondroplasia. Pfizer will pay...
BC Innovations | Mar 22, 2019
Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
BC Week In Review | Sep 13, 2018
Company News

Zealand brings in $205M for pipeline via royalty pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million....
BC Extra | Sep 6, 2018
Company News

Zealand brings in $205M for pipeline via Royalty Pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million....
BC Innovations | May 1, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Inflammatory bowel disease (IBD) Mouse studies identified a peptide-based GLP-2R activator that could help treat IBD. Chemical synthesis and testing in a cell-based activity assay of GLP-2-based stapled peptides yielded a peptide that activated...
BC Week In Review | Jul 28, 2017
Clinical News

Zealand's glepaglutide meets in Phase II for SBS

Zealand Pharma A/S (CSE:ZEAL) reported data from a Phase II trial in 16 patients with short bowel syndrome (SBS) showing that once-daily subcutaneous glepaglutide (ZP1848) met the primary endpoint of reducing fecal wet weight output...
BC Extra | Jul 21, 2017
Preclinical News

Researchers suggest inhibiting DPP-4 could help treat colitis

In a paper published in the Journal of Pharmacology and Experimental Therapeutics , researchers from the Medical University of Lodz and the University of Gdansk showed that inhibiting dipeptidyl peptidase-4 ( DPP-4 ; CD26) could help treat...
BC Extra | Jul 7, 2017
Financial News

Zealand planning NASDAQ listing

Metabolic company Zealand Pharma A/S (CSE:ZEAL) filed to raise up to $86.3 million via a listing of ADSs on NASDAQ underwritten by Morgan Stanley and Goldman Sachs. Zealand's partner Sanofi (Euronext:SAN; NYSE:SNY) markets the company's...
Items per page:
1 - 10 of 136